Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-1|1|2|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-2|1|3|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-3|1|3|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-4|1|3|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-5|1|5|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-6|1|7|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-7|1|7|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-8|1|9|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-9|1|9|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-10|1|11|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-11|1|12|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-12|1|16|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-13|1|20|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-14|1|22|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-15|1|26|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-16|1|27|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-17|1|32|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-18|1|33|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-19|1|38|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-20|1|39|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-21|1|44|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-22|1|44|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-23|1|46|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-24|1|54|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-25|1|54|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-26|1|61|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-27|1|64|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-28|1|64|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-29|1|66|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-30|1|72|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-31|1|75|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-32|1|79|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-33|1|81|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-34|1|84|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-35|1|84|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-36|1|109|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-37|1|109|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-38|1|116|Neoplasia malignant|Reproductive system,MA: 0000326 - reproductive system|metastatic,MPATH: 242 - hemangiosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-39|1|116|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-40|1|132|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-41|1|134|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-42|1|136|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-43|1|407|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-44|1|467|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-45|1|525|Neoplasia malignant|Lymphatic vessels among cardiovascular system|benign|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-46|1|532|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-47|1|560|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-48|1|569|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-49|1|594|Other deterministic changes|Whole body|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-50|1|605|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-51|1|613|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-52|1|641|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-53|1|658|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-54|1|668|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-55|1|670|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-56|1|675|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-57|1|676|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-58|1|676|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-59|1|682|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-60|1|683|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-61|1|693|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-62|1|715|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-63|1|720|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-64|1|721|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|metastatic,MPATH: 551 - sarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-65|1|738|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-66|1|740|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-67|1|746|Hyperplastic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-68|1|749|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-69|1|754|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-70|1|756|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 409 - fibrous histiocytoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-71|1|762|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-72|1|765|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-73|1|784|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-74|1|793|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-75|1|797|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-76|1|798|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-77|1|800|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-78|1|801|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-79|1|804|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-80|1|808|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-81|1|812|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-82|1|818|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-83|1|826|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-84|1|827|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-85|1|836|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-86|1|848|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-87|1|849|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-88|1|850|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-89|1|850|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-90|1|852|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-91|1|852|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-92|1|856|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-93|1|856|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-94|1|856|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-95|1|856|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-96|1|858|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-97|1|861|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-98|1|868|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-99|1|880|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-100|1|881|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-101|1|883|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-102|1|887|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-103|1|891|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-104|1|893|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-105|1|901|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-106|1|902|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-107|1|905|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-108|1|905|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-109|1|905|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-110|1|907|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-111|1|907|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-112|1|912|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-113|1|915|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-114|1|927|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-115|1|928|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-116|1|930|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-117|1|940|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-118|1|940|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-119|1|944|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-120|1|945|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-121|1|946|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-122|1|953|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-123|1|955|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-124|1|959|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|metastatic,MPATH: 322 - teratoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-125|1|961|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-126|1|965|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-127|1|968|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|metastatic,MPATH: 551 - sarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-128|1|972|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-129|1|973|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-130|1|974|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-131|1|975|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-132|1|975|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-133|1|979|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-134|1|980|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-135|1|980|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-136|1|984|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-137|1|984|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-138|1|985|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-139|1|988|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-140|1|989|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-141|1|991|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-142|1|992|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-143|1|993|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-144|1|999|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-145|1|999|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-146|1|1150|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-147|1|1150|Other deterministic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-148|1|1154|Hyperplastic changes|Lower respiratory system|n/a|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-149|1|1155|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|,MPATH: 218 - neoplasm|
2-12-1|NETR-Gy 0.012,8/79|1|92|neutrons fission|0.012|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-1-150|1|1156|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-1|2|7|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-2|2|8|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-3|2|8|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-4|2|9|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-5|2|11|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-6|2|11|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-7|2|12|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-8|2|18|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-9|2|29|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-10|2|32|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-11|2|33|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-12|2|37|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-13|2|39|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-14|2|39|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-15|2|45|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-16|2|45|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-17|2|46|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-18|2|48|Other deterministic changes|Whole body|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-19|2|50|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-20|2|51|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-21|2|57|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-22|2|59|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-23|2|60|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-24|2|63|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-25|2|64|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-26|2|65|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-27|2|66|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-28|2|69|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-29|2|75|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-30|2|75|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 219 - adnexal and skin appendage tumor|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-31|2|82|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-32|2|84|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-33|2|90|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-34|2|326|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-35|2|337|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|,MPATH: 242 - hemangiosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-36|2|363|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-37|2|430|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-38|2|521|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-39|2|605|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-40|2|629|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-41|2|667|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-42|2|667|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-43|2|672|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-44|2|674|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-45|2|683|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-46|2|687|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-47|2|688|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-48|2|693|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-49|2|698|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-50|2|709|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-51|2|713|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-52|2|716|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-53|2|736|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-54|2|738|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-55|2|738|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-56|2|741|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-57|2|749|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-58|2|766|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-59|2|770|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-60|2|775|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-61|2|776|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-62|2|786|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-63|2|787|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-64|2|801|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-65|2|808|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-66|2|809|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-67|2|813|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-68|2|813|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-69|2|813|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-70|2|819|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-71|2|824|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-72|2|827|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-73|2|829|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-74|2|829|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-75|2|830|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 409 - fibrous histiocytoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-76|2|832|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-77|2|838|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-78|2|850|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-79|2|850|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-80|2|850|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-81|2|851|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-82|2|851|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-83|2|853|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-84|2|857|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-85|2|858|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-86|2|859|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-87|2|862|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-88|2|866|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-89|2|868|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-90|2|869|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-91|2|872|Neoplasia benign|Bloodvessels among cardiovascular system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-92|2|872|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-93|2|875|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-94|2|877|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-95|2|880|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-96|2|883|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-97|2|888|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-98|2|893|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-99|2|893|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-100|2|894|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-101|2|899|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-102|2|905|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-103|2|909|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-104|2|911|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-105|2|912|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-106|2|913|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-107|2|913|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-108|2|917|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-109|2|919|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-110|2|919|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-111|2|919|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-112|2|921|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-113|2|925|Hyperplastic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-114|2|925|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-115|2|926|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-116|2|930|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-117|2|931|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-118|2|931|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-119|2|934|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-120|2|937|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-121|2|937|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-122|2|938|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-123|2|943|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-124|2|945|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-125|2|946|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-126|2|948|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-127|2|948|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-128|2|950|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-129|2|956|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-130|2|956|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-131|2|960|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-132|2|960|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-133|2|962|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-134|2|964|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-135|2|969|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-136|2|971|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-137|2|973|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-138|2|979|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-139|2|980|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-140|2|981|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-141|2|982|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-142|2|983|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-143|2|983|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-144|2|989|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-145|2|989|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-146|2|990|Other deterministic changes|Lower respiratory system|n/a|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-147|2|990|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-148|2|1153|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-149|2|1155|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-2|NETR-Gy 0.02,8/79|1|92|neutrons fission|0.02|grays|External exposure|Triton|150 (150 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-2-150|2|1156|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-1|3|209|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-2|3|229|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-3|3|333|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-4|3|350|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-5|3|353|Other deterministic changes|Whole body|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-6|3|382|Other deterministic changes|Whole body|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-7|3|441|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-8|3|460|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-9|3|521|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-10|3|528|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-11|3|571|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-12|3|578|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-13|3|602|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-14|3|616|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-15|3|616|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-16|3|620|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-17|3|635|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-18|3|639|Other deterministic changes|Whole body|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-19|3|648|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-20|3|664|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-21|3|683|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-22|3|694|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-23|3|699|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-24|3|711|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-25|3|711|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-26|3|715|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-27|3|718|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-28|3|718|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-29|3|730|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-30|3|735|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|benign,MPATH: 426 - leiomyosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-31|3|741|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-32|3|762|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-33|3|763|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-34|3|786|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-35|3|787|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-36|3|787|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-37|3|790|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-38|3|796|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-39|3|806|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-40|3|810|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-41|3|810|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-42|3|811|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-43|3|816|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-44|3|817|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-45|3|817|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-46|3|818|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-47|3|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-48|3|823|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-49|3|823|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-50|3|824|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-51|3|832|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-52|3|832|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-53|3|833|Neoplasia malignant|Heart among cardiovascular system,MA: 0000072 - heart|metastatic,MPATH: 511 - Myeloproliferation (genetic)|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-54|3|833|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-55|3|854|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-56|3|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-57|3|855|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-58|3|861|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-59|3|861|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-60|3|863|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-61|3|880|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-62|3|881|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-63|3|881|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-64|3|881|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-65|3|895|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-66|3|895|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-67|3|897|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-68|3|900|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-69|3|907|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-70|3|910|Neoplasia malignant|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-71|3|918|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-72|3|918|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-73|3|923|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-74|3|929|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-75|3|930|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-76|3|936|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-77|3|937|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-78|3|938|Other deterministic changes|Lower respiratory system|n/a|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-79|3|938|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-3|NETR-Gy 0.06,5/79|1|92|neutrons fission|0.06|grays|External exposure|Triton|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-3-80|3|939|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-1|4|388|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-2|4|438|Other deterministic changes|Whole body|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-3|4|454|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-4|4|474|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-5|4|499|Other deterministic changes|Whole body|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-6|4|519|Neoplasia unclassified|Lower respiratory system,MA: 0000032 - thoracic cavity|,MPATH: 238 - hemangioblastoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-7|4|533|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-8|4|575|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-9|4|592|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-10|4|599|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-11|4|618|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-12|4|629|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-13|4|631|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-14|4|634|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-15|4|638|Neoplasia benign|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-16|4|640|Other deterministic changes|Whole body|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-17|4|641|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-18|4|666|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-19|4|668|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-20|4|674|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-21|4|679|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-22|4|680|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-23|4|686|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-24|4|689|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-25|4|689|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-26|4|690|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-27|4|690|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-28|4|690|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-29|4|697|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-30|4|701|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-31|4|705|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-32|4|706|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-33|4|709|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-34|4|726|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-35|4|727|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-36|4|728|Hyperplastic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-37|4|731|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-38|4|733|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-39|4|743|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-40|4|749|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-41|4|749|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-42|4|751|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-43|4|757|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-44|4|759|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-45|4|759|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-46|4|759|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-47|4|762|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-48|4|768|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-49|4|799|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-50|4|801|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-51|4|807|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-52|4|810|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-53|4|814|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-54|4|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-55|4|822|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-56|4|823|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-57|4|849|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-58|4|850|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-59|4|853|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-60|4|853|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-61|4|853|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-62|4|853|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 409 - fibrous histiocytoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-63|4|859|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-64|4|860|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-65|4|870|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-66|4|881|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 409 - fibrous histiocytoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-67|4|885|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-68|4|885|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-69|4|888|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-70|4|888|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-71|4|894|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-72|4|895|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-73|4|896|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-74|4|901|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-75|4|906|Other deterministic changes|Lower respiratory system|n/a|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-76|4|908|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-77|4|933|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-4|NETR-Gy 0.1,5/78|1|92|neutrons fission|0.1|grays|External exposure|Triton|78 (78 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-4-78|4|935|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-1|5|61|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-2|5|201|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-3|5|237|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-4|5|296|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-5|5|407|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-6|5|434|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-7|5|461|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 409 - fibrous histiocytoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-8|5|480|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-9|5|480|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-10|5|496|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-11|5|501|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-12|5|506|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-13|5|517|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-14|5|571|Other deterministic changes|Whole body|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-15|5|575|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-16|5|577|Other deterministic changes|Whole body|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-17|5|597|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-18|5|598|Neoplasia malignant|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-19|5|608|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-20|5|609|Hyperplastic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-21|5|621|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-22|5|634|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-23|5|634|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-24|5|634|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-25|5|635|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-26|5|641|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-27|5|643|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-28|5|645|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-29|5|645|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-30|5|651|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-31|5|653|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-32|5|658|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|benign,MPATH: 446 - squamous cell carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-33|5|664|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-34|5|677|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-35|5|677|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-36|5|682|Neoplasia malignant|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-37|5|684|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-38|5|686|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-39|5|686|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-40|5|689|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-41|5|692|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-42|5|692|Other deterministic changes|Whole body|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-43|5|699|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-44|5|700|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-45|5|701|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-46|5|704|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-47|5|705|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|metastatic,MPATH: 551 - sarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-48|5|725|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-49|5|733|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-50|5|733|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-51|5|733|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-52|5|741|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-53|5|745|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-54|5|745|Neoplasia unclassified|Reproductive system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-55|5|746|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-56|5|759|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-57|5|760|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-58|5|769|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-59|5|774|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-60|5|780|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-61|5|783|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-62|5|783|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-63|5|785|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-64|5|788|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-65|5|788|Neoplasia malignant|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-66|5|788|Neoplasia malignant|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-67|5|788|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-68|5|810|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-69|5|822|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-70|5|829|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-71|5|829|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-72|5|835|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-73|5|835|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-74|5|836|Other deterministic changes|Lower respiratory system|n/a|
2-12-5|NETR-Gy 0.32,4/78|1|92|neutrons fission|0.32|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-5-75|5|836|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-1|6|187|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-2|6|228|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-3|6|237|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-4|6|339|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-5|6|367|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-6|6|384|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-7|6|390|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-8|6|412|Neoplasia unclassified|Central nervous system among nervous system|metastatic|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-9|6|430|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-10|6|433|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-11|6|460|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-12|6|465|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-13|6|479|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-14|6|484|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-15|6|486|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-16|6|495|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|metastatic,MPATH: 365 - mesothelioma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-17|6|506|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-18|6|514|Neoplasia benign|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-19|6|518|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-20|6|520|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-21|6|532|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-22|6|544|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-23|6|544|Neoplasia benign|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-24|6|550|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-25|6|553|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-26|6|559|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-27|6|565|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-28|6|576|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-29|6|579|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-30|6|579|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|,MPATH: 322 - teratoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-31|6|580|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-32|6|586|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-33|6|591|Other deterministic changes|Whole body|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-34|6|596|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-35|6|600|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-36|6|602|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-37|6|607|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-38|6|617|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-39|6|626|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-40|6|633|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-41|6|635|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-42|6|637|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-43|6|642|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-44|6|656|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-45|6|664|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-46|6|665|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-47|6|667|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-48|6|668|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-49|6|668|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-50|6|668|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-51|6|669|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-52|6|673|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-53|6|677|Neoplasia malignant|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-54|6|677|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-55|6|682|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-56|6|685|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-57|6|699|Other deterministic changes|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-58|6|706|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-59|6|712|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-60|6|718|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-61|6|720|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-62|6|722|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-63|6|726|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-64|6|726|Neoplasia malignant|Lower respiratory system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-65|6|734|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-66|6|740|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-67|6|745|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-68|6|746|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-69|6|747|Neoplasia unclassified|Reproductive system|n/a|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-70|6|769|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-71|6|770|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-72|6|783|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|metastatic,MPATH: 551 - sarcoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-73|6|815|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-74|6|824|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-6|NETR-Gy 0.49,4/78|1|92|neutrons fission|0.49|grays|External exposure|Triton|75 (75 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-6-75|6|836|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-1|7|241|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-2|7|271|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-3|7|271|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-4|7|297|Other deterministic changes|Whole body|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-5|7|308|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|,MPATH: 322 - teratoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-6|7|349|Other deterministic changes|Whole body|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-7|7|361|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-8|7|370|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-9|7|374|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-10|7|378|Other deterministic changes|Whole body|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-11|7|388|Other deterministic changes|Whole body|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-12|7|388|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 409 - fibrous histiocytoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-13|7|388|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-14|7|388|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-15|7|397|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-16|7|397|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-17|7|409|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-18|7|426|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-19|7|426|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|benign,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-20|7|428|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-21|7|430|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-22|7|433|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-23|7|439|Other deterministic changes|Whole body|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-24|7|444|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-25|7|448|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-26|7|448|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-27|7|453|Other deterministic changes|Whole body|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-28|7|455|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-29|7|455|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-30|7|458|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-31|7|460|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-32|7|460|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-33|7|461|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-34|7|465|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-35|7|467|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-36|7|467|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-37|7|469|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-38|7|480|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-39|7|481|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-40|7|483|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-41|7|488|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-42|7|499|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-43|7|503|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-44|7|515|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-45|7|519|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-46|7|526|Other deterministic changes|Whole body|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-47|7|535|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-48|7|536|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-49|7|537|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-50|7|543|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-51|7|547|Neoplasia malignant|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-52|7|548|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-53|7|552|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-54|7|557|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-55|7|557|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-56|7|557|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-57|7|557|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-58|7|564|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-59|7|566|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-60|7|576|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-61|7|584|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-62|7|587|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-63|7|588|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-64|7|590|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-65|7|600|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-66|7|605|Neoplasia malignant|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-67|7|606|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-68|7|610|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-69|7|629|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-70|7|639|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-71|7|641|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-72|7|642|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-73|7|643|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-74|7|644|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-75|7|652|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-76|7|653|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-77|7|655|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|metastatic,MPATH: 365 - mesothelioma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-78|7|662|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-79|7|671|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-80|7|671|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-81|7|672|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-82|7|673|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-83|7|674|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-84|7|674|Neoplasia malignant|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-85|7|675|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-86|7|675|Neoplasia unclassified|Reproductive system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-87|7|676|Hyperplastic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-88|7|676|Neoplasia malignant|Reproductive system,MA: 0000381 - female reproductive system|,MPATH: 549 - carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-89|7|677|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-90|7|698|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-91|7|704|Neoplasia benign|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-92|7|707|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-93|7|707|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-94|7|709|Neoplasia benign|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-95|7|713|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-96|7|713|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-97|7|714|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-98|7|714|Neoplasia unclassified|Reproductive system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-99|7|714|Hyperplastic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-100|7|715|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|benign,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-101|7|717|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-102|7|718|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-103|7|721|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-104|7|732|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-105|7|734|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-106|7|734|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-107|7|740|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-108|7|740|Hyperplastic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-109|7|743|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-110|7|743|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-111|7|749|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-112|7|752|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-113|7|752|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-114|7|753|Other deterministic changes|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-115|7|753|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-116|7|754|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-117|7|754|Neoplasia malignant|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-118|7|755|Neoplasia benign|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-119|7|755|Neoplasia benign|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-120|7|755|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-121|7|776|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-122|7|790|Neoplasia malignant|Lower respiratory system|n/a|
2-12-7|NETR-Gy 1.5,9/77|1|92|neutrons fission|1.5|grays|External exposure|Triton|123 (123 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-7-123|7|801|Neoplasia malignant|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-1|8|238|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-2|8|281|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-3|8|287|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-4|8|292|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-5|8|310|Other deterministic changes|Whole body|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-6|8|336|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-7|8|341|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-8|8|347|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-9|8|347|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-10|8|356|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-11|8|358|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-12|8|376|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 218 - neoplasm|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-13|8|379|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-14|8|386|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-15|8|408|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-16|8|411|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-17|8|411|Neoplasia malignant|Lymphatic vessels among cardiovascular system|benign|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-18|8|414|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-19|8|414|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-20|8|429|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-21|8|429|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-22|8|433|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-23|8|437|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-24|8|437|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-25|8|439|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-26|8|439|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-27|8|439|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-28|8|441|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-29|8|442|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-30|8|442|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-31|8|443|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-32|8|471|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-33|8|475|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-34|8|476|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-35|8|480|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-36|8|482|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-37|8|484|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-38|8|488|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-39|8|489|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-40|8|499|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-41|8|511|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-42|8|514|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-43|8|520|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-44|8|533|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-45|8|535|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-46|8|537|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-47|8|537|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-48|8|537|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-49|8|537|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-50|8|537|Neoplasia malignant|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-51|8|537|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-52|8|538|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-53|8|538|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-54|8|538|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-55|8|546|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-56|8|547|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-57|8|550|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-58|8|560|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-59|8|565|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-60|8|566|Neoplasia malignant|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-61|8|571|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-62|8|581|Neoplasia malignant|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-63|8|581|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-64|8|581|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-65|8|593|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-66|8|598|Neoplasia malignant|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-67|8|601|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-68|8|602|Hyperplastic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-69|8|603|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-70|8|603|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-71|8|605|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-72|8|615|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-73|8|617|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-74|8|617|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-75|8|620|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-76|8|622|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-77|8|622|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-78|8|623|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-79|8|636|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-80|8|642|Hyperplastic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-81|8|643|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-82|8|646|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-83|8|654|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-84|8|655|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-85|8|655|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-86|8|655|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-87|8|656|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-88|8|657|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-89|8|666|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-90|8|667|Other deterministic changes|Lower respiratory system|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-91|8|669|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-92|8|679|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-93|8|679|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-94|8|680|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-95|8|680|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-96|8|693|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-97|8|699|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-98|8|701|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-99|8|702|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-100|8|702|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-101|8|706|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-102|8|722|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-103|8|724|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 242 - hemangiosarcoma|
2-12-8|NETR-Gy 2.3,77-79|1|92|neutrons fission|2.3|grays|External exposure|Triton|104 (104 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-8-104|8|757|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-1|9|239|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-2|9|254|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-3|9|259|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-4|9|337|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-5|9|353|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-6|9|380|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-7|9|382|Other deterministic changes|Lower respiratory system|n/a|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-8|9|429|Other deterministic changes|Lower respiratory system|n/a|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-9|9|431|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-10|9|444|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-11|9|444|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-12|9|452|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-13|9|463|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-14|9|472|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-15|9|492|Other deterministic changes|Lower respiratory system|n/a|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-16|9|494|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-17|9|578|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-18|9|583|Neoplasia malignant|Lower respiratory system|n/a|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-19|9|617|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-9|NETR-Gy 2.4,11/76|1|92|neutrons fission|2.4|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-9-20|9|625|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-1|10|290|Other deterministic changes|Lower respiratory system|n/a|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-2|10|295|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-3|10|300|Other deterministic changes|Lower respiratory system|n/a|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-4|10|313|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-5|10|324|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-6|10|364|Other deterministic changes|Lower respiratory system|n/a|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-7|10|379|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-8|10|388|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-9|10|404|Other deterministic changes|Lower respiratory system|n/a|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-10|10|409|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-11|10|469|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-12|10|506|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-13|10|508|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-14|10|513|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-15|10|513|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-16|10|528|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-17|10|576|Other deterministic changes|Lower respiratory system|n/a|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-18|10|611|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-19|10|618|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-10|NETR-Gy 2.54,5/78|1|92|neutrons fission|2.54|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-10-20|10|618|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-11|NETR-Gy 2.8,5/80|1|92|neutrons fission|2.8|grays|External exposure|Triton|6 (0 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|No information on individuals available for this study
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-1|12|187|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-2|12|231|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-3|12|299|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-4|12|310|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-5|12|316|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-6|12|323|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-7|12|326|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-8|12|350|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-9|12|358|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-10|12|358|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-11|12|358|Other deterministic changes|Whole body|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-12|12|358|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-13|12|360|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-14|12|361|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-15|12|374|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-16|12|378|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-17|12|387|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-18|12|387|Other deterministic changes|Whole body|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-19|12|404|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-20|12|418|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-21|12|424|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-22|12|434|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-23|12|434|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-24|12|440|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-25|12|442|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-26|12|449|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-27|12|469|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-28|12|471|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-29|12|471|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-30|12|484|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-31|12|488|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-32|12|490|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-33|12|493|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-34|12|498|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-35|12|500|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-36|12|504|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-37|12|512|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-38|12|517|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-39|12|522|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-40|12|527|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-41|12|527|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-42|12|527|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-43|12|537|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 218 - neoplasm|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-44|12|546|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-45|12|548|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-46|12|548|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-47|12|548|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-48|12|549|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-49|12|554|Neoplasia malignant|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-50|12|560|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-51|12|570|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-52|12|588|Neoplasia malignant|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-53|12|589|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-54|12|601|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-55|12|606|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-56|12|606|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-57|12|608|Neoplasia malignant|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-58|12|628|Other deterministic changes|Lower respiratory system|n/a|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-59|12|629|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-12-12|NETR-Gy 3.5,80-81|1|92|neutrons fission|3.5|grays|External exposure|Triton|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-12-60|12|629|Other deterministic changes|Lower respiratory system|n/a|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-1|13|167|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-2|13|232|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-3|13|237|Other deterministic changes|Lower respiratory system|n/a|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-4|13|268|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-5|13|339|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-6|13|359|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-7|13|388|Other deterministic changes|Lower respiratory system|n/a|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-8|13|394|Other deterministic changes|Lower respiratory system|n/a|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-9|13|401|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-10|13|437|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-11|13|443|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-12|13|454|Other deterministic changes|Lower respiratory system|n/a|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-13|13|456|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-14|13|477|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-15|13|486|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-16|13|513|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-17|13|535|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-18|13|535|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-19|13|540|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-13|NETR-Gy 3.86,11/76|1|92|neutrons fission|3.86|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-13-20|13|549|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-1|14|200|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-2|14|257|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-3|14|263|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|,MPATH: 446 - squamous cell carcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-4|14|267|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-5|14|274|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-6|14|277|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-7|14|278|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-8|14|336|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-9|14|336|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-10|14|357|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-11|14|361|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-12|14|370|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-13|14|381|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-14|14|386|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-15|14|417|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-16|14|417|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-17|14|429|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-18|14|434|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-19|14|440|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-20|14|448|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-21|14|451|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-22|14|451|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-23|14|456|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-24|14|459|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-25|14|462|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-26|14|469|Other deterministic changes|Whole body|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-27|14|480|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-28|14|484|Other deterministic changes|Whole body|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-29|14|484|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-30|14|497|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-31|14|502|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-32|14|503|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-33|14|511|Neoplasia malignant|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-34|14|519|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-35|14|525|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-36|14|525|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-37|14|525|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-38|14|529|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-39|14|532|Other deterministic changes|Lower respiratory system|n/a|
2-12-14|NETR-Gy 4.4,11/81|1|92|neutrons fission|4.4|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-14-40|14|532|Hyperplastic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-1|15|54|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-2|15|54|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-3|15|55|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-4|15|55|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-5|15|55|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-6|15|55|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-7|15|55|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-8|15|56|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-9|15|56|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-10|15|56|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-11|15|56|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-12|15|56|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-13|15|56|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-14|15|56|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-15|15|56|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-16|15|56|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-17|15|57|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-18|15|57|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-19|15|58|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-20|15|61|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-21|15|190|Other deterministic changes|Whole body|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-22|15|215|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-23|15|219|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-24|15|268|Other deterministic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-25|15|293|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-26|15|333|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-27|15|337|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 551 - sarcoma|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-28|15|337|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 549 - carcinoma|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-29|15|380|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-30|15|397|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|,MPATH: 322 - teratoma|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-31|15|401|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-32|15|411|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-33|15|429|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-34|15|435|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-35|15|455|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-36|15|465|Hyperplastic changes|Lower respiratory system|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-37|15|471|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-38|15|471|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-39|15|513|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-15|NETR-Gy 5.3,10/76|1|92|neutrons fission|5.3|grays|External exposure|Triton|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-15-40|15|562|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-1|16|267|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-2|16|317|Neoplasia benign|Lower respiratory system|n/a|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-3|16|344|Other deterministic changes|Lower respiratory system|n/a|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-4|16|354|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-5|16|361|Other deterministic changes|Lower respiratory system|n/a|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-6|16|361|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-7|16|361|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-8|16|370|Hyperplastic changes|Lower respiratory system|n/a|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-9|16|393|Other deterministic changes|Lower respiratory system|n/a|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-10|16|406|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-11|16|406|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-12|16|409|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-13|16|409|Other deterministic changes|Lower respiratory system|n/a|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-14|16|409|Hyperplastic changes|Lower respiratory system|n/a|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-15|16|422|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-16|16|424|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-17|16|444|Other deterministic changes|Lower respiratory system|n/a|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-18|16|449|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-19|16|476|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-12-16|NETR-Gy 6,n/a|1|92|neutrons fission|6|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-16-20|16|482|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-1|17|148|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-2|17|191|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-3|17|203|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-4|17|206|Other deterministic changes|Lower respiratory system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-5|17|223|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-6|17|225|Other deterministic changes|Lower respiratory system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-7|17|225|Other deterministic changes|Lower respiratory system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-8|17|237|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-9|17|244|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-10|17|255|Other deterministic changes|Lower respiratory system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-11|17|255|Other deterministic changes|Lower respiratory system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-12|17|279|Other deterministic changes|Lower respiratory system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-13|17|279|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-14|17|294|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-15|17|302|Other deterministic changes|Lower respiratory system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-16|17|316|Other deterministic changes|Lower respiratory system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-17|17|317|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-18|17|317|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-19|17|331|Other deterministic changes|Lower respiratory system|n/a|
2-12-17|NETR-Gy 8,n/a|1|92|neutrons fission|8|grays|External exposure|Triton|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-17-20|17|331|Neoplasia malignant|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-1|18|65|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-2|18|97|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-3|18|220|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-4|18|304|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-5|18|330|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-6|18|333|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-7|18|333|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-8|18|337|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-9|18|361|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-10|18|374|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-11|18|386|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-12|18|396|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-13|18|400|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-14|18|407|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-15|18|418|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-16|18|438|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-17|18|439|Neoplasia benign|Bloodvessels among cardiovascular system|benign|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-18|18|439|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-19|18|452|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-20|18|452|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-21|18|456|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-22|18|480|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-23|18|492|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-24|18|493|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-25|18|514|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-26|18|535|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-27|18|554|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-28|18|562|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-29|18|562|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-30|18|562|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-31|18|562|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-32|18|575|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-33|18|580|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-34|18|588|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-35|18|588|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-36|18|588|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-37|18|610|Neoplasia unclassified|Reproductive system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-38|18|616|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-39|18|624|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-40|18|624|Neoplasia benign|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-41|18|641|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-42|18|641|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-43|18|653|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-44|18|653|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-45|18|653|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-46|18|666|Neoplasia benign|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-47|18|670|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-48|18|671|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-49|18|675|Hyperplastic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-50|18|678|Hyperplastic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-51|18|678|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-52|18|678|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-53|18|678|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-54|18|680|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-55|18|682|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-56|18|683|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-57|18|694|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-58|18|704|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-59|18|704|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-60|18|712|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 409 - fibrous histiocytoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-61|18|715|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-62|18|719|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-63|18|719|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-64|18|730|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-65|18|730|Neoplasia unclassified|Lower respiratory system,MA: 0000032 - thoracic cavity|,MPATH: 238 - hemangioblastoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-66|18|737|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-67|18|737|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-68|18|739|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-69|18|739|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-70|18|739|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-71|18|753|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|benign,MPATH: 242 - hemangiosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-72|18|753|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-73|18|758|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-74|18|761|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-75|18|761|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-76|18|762|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-77|18|762|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-78|18|765|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-79|18|769|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-80|18|771|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-81|18|771|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-82|18|772|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-83|18|772|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-84|18|782|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-85|18|783|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-86|18|794|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 409 - fibrous histiocytoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-87|18|795|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-88|18|803|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-89|18|807|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-90|18|808|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-91|18|817|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-92|18|817|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-93|18|817|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-94|18|817|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-95|18|818|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-96|18|825|Hyperplastic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-97|18|825|Neoplasia malignant|Reproductive system,MA: 0000404 - prostate gland|,MPATH: 268 - adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-98|18|828|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-99|18|828|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-100|18|831|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-101|18|831|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-102|18|842|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-103|18|844|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-104|18|844|Neoplasia benign|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-105|18|844|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-106|18|844|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-107|18|844|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-108|18|870|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-109|18|874|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-110|18|881|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-111|18|895|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-112|18|904|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-113|18|912|Other deterministic changes|Lower respiratory system|n/a|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-114|18|948|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-115|18|954|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-18|NESI-Gy 0.4,10/79|1|92|neutrons fission|0.4|grays|External exposure|Silene|116 (116 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-18-116|18|954|Neoplasia benign|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-1|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-2|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-3|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-4|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-5|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-6|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-7|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-8|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-9|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-10|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-11|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-12|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-13|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-14|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-15|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-16|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-17|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-18|19|36|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-19|19|103|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-20|19|119|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-21|19|176|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-22|19|190|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-23|19|227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-24|19|229|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-25|19|238|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-26|19|238|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-27|19|240|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-28|19|240|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-29|19|241|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-30|19|244|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-31|19|247|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-32|19|265|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-33|19|269|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-34|19|281|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-35|19|292|Other deterministic changes|Whole body|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-36|19|297|Other deterministic changes|Whole body|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-37|19|316|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-38|19|319|Other deterministic changes|Whole body|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-39|19|320|Other deterministic changes|Whole body|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-40|19|323|Other deterministic changes|Whole body|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-41|19|324|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-42|19|332|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-43|19|336|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|metastatic,MPATH: 268 - adenocarcinoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-44|19|351|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-45|19|371|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-46|19|398|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-47|19|422|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-48|19|428|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-49|19|428|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-50|19|428|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-51|19|434|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-52|19|440|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-53|19|441|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-54|19|442|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-55|19|446|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-56|19|446|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-57|19|447|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-58|19|456|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-59|19|462|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-60|19|462|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-61|19|466|Hyperplastic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-62|19|476|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-63|19|509|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-64|19|525|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-65|19|545|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-66|19|546|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-67|19|555|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-68|19|555|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-69|19|558|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-70|19|558|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-71|19|561|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-72|19|573|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-73|19|581|Hyperplastic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-74|19|583|Hyperplastic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-75|19|590|Other deterministic changes|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-76|19|603|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-77|19|637|Neoplasia benign|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-78|19|639|Neoplasia benign|Lower respiratory system|n/a|
2-12-19|NESIa-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|79 (79 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-19-79|19|695|Other deterministic changes|Whole body|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-1|20|143|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-2|20|154|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-3|20|157|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-4|20|188|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-5|20|197|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-6|20|205|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-7|20|216|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|metastatic,MPATH: 268 - adenocarcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-8|20|220|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-9|20|223|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-10|20|225|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-11|20|230|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-12|20|237|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-13|20|237|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-14|20|237|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-15|20|244|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-16|20|251|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-17|20|254|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-18|20|254|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-19|20|254|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-20|20|258|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-21|20|262|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-22|20|265|Hyperplastic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-23|20|265|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-24|20|265|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-25|20|279|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-26|20|279|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-27|20|282|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-28|20|283|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-29|20|286|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-30|20|286|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-31|20|294|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-32|20|295|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-33|20|300|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-34|20|313|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-35|20|334|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-36|20|335|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-37|20|337|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-38|20|345|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-39|20|349|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-40|20|349|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-41|20|351|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-42|20|352|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-43|20|352|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-44|20|357|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-45|20|360|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-46|20|362|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-47|20|366|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-48|20|370|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 418 - liposarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-49|20|372|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-50|20|376|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-51|20|379|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-52|20|384|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-53|20|385|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|metastatic,MPATH: 218 - neoplasm|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-54|20|389|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-55|20|390|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-56|20|390|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-57|20|390|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-58|20|394|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-59|20|398|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-60|20|400|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-61|20|401|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-62|20|404|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-63|20|404|Neoplasia malignant|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-64|20|408|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-65|20|411|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-66|20|411|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-67|20|413|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-68|20|413|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-69|20|418|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|metastatic,MPATH: 242 - hemangiosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-70|20|418|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-71|20|420|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-72|20|422|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-73|20|425|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-74|20|425|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-75|20|427|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-76|20|429|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-77|20|429|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-78|20|433|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-79|20|433|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-80|20|439|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-81|20|440|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-82|20|442|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-83|20|448|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-84|20|449|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-85|20|450|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-86|20|460|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-87|20|460|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-88|20|461|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-89|20|462|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-90|20|463|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-91|20|464|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-92|20|465|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-93|20|469|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-94|20|471|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-95|20|482|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-96|20|484|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-97|20|486|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-98|20|489|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-99|20|490|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-100|20|492|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|benign,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-101|20|495|Neoplasia malignant|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-102|20|495|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-103|20|499|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-104|20|503|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-105|20|504|Hyperplastic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-106|20|506|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-107|20|511|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-108|20|511|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-109|20|513|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-110|20|513|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-111|20|518|Neoplasia malignant|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-112|20|520|Other deterministic changes|Lower respiratory system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-113|20|523|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-114|20|524|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-115|20|526|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-116|20|530|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-117|20|532|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-118|20|532|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-20|NESIb-Gy 0.6,n/a|1|92|neutrons fission|0.6|grays|External exposure|Silene|200 (119 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study SILENE 0,6 Gy  3.9.91 50 77650-77700|2-12-20-119|20|533|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-1|21|2|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-2|21|3|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-3|21|3|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-4|21|5|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-5|21|6|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-6|21|8|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-7|21|9|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-8|21|11|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-9|21|11|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-10|21|13|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-11|21|13|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-12|21|13|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-13|21|15|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-14|21|16|Neoplasia malignant|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-15|21|16|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-16|21|18|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-17|21|20|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-18|21|21|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-19|21|22|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-20|21|22|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-21|21|26|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-22|21|26|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-23|21|26|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-24|21|28|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-25|21|30|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-26|21|31|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-27|21|32|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-28|21|33|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-29|21|37|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-30|21|37|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-31|21|40|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-32|21|41|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-33|21|45|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-34|21|47|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-35|21|47|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-36|21|48|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-37|21|48|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-38|21|52|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-39|21|53|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-40|21|57|Neoplasia malignant|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-41|21|58|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-42|21|58|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-43|21|59|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-44|21|61|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-45|21|62|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-46|21|62|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-47|21|62|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-48|21|65|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-49|21|67|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-50|21|67|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-51|21|67|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-52|21|68|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-53|21|68|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-54|21|69|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-55|21|69|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-56|21|70|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-57|21|70|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-58|21|73|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-59|21|73|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-60|21|73|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-61|21|74|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-62|21|76|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-63|21|83|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-64|21|83|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-65|21|84|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-66|21|86|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-67|21|87|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-68|21|89|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-69|21|89|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-70|21|89|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-71|21|90|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-72|21|93|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-73|21|93|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-74|21|93|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-75|21|94|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-76|21|97|Neoplasia malignant|Adrenal gland  among endocrine systems|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-77|21|98|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-78|21|99|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-79|21|99|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-80|21|100|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-81|21|100|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-82|21|103|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-83|21|104|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|metastatic,MPATH: 365 - mesothelioma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-84|21|105|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-85|21|107|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-86|21|107|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-87|21|108|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-88|21|109|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-89|21|111|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-90|21|111|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-91|21|112|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-92|21|112|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-93|21|113|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-94|21|114|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-95|21|114|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-96|21|116|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-97|21|117|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-98|21|119|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-99|21|119|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-100|21|124|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-101|21|126|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-102|21|128|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-103|21|131|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-104|21|134|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-105|21|136|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-106|21|136|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-107|21|137|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-108|21|138|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-109|21|143|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-110|21|145|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-111|21|149|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-112|21|149|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-113|21|149|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-114|21|154|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-115|21|154|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-116|21|154|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-117|21|154|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-118|21|154|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-119|21|154|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-120|21|154|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-121|21|177|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-122|21|181|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-123|21|194|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-124|21|199|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-125|21|202|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-126|21|218|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-127|21|218|Other deterministic changes|Whole body|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-128|21|222|Neoplasia malignant|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-129|21|227|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-130|21|233|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-131|21|576|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-132|21|607|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-133|21|614|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-134|21|624|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-135|21|627|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-136|21|632|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-137|21|633|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-138|21|640|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|metastatic,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-139|21|641|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-140|21|645|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-141|21|647|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-142|21|648|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-143|21|655|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-144|21|660|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-145|21|673|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-146|21|681|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-147|21|684|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-148|21|686|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-149|21|687|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-150|21|695|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-151|21|698|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-152|21|698|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-153|21|708|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-154|21|722|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-155|21|722|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-156|21|730|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-157|21|731|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-158|21|733|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-159|21|740|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-160|21|740|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-161|21|740|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-162|21|746|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-163|21|747|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-164|21|749|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-165|21|754|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-166|21|758|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-167|21|759|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-168|21|762|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|metastatic,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-169|21|764|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-170|21|766|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-171|21|769|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-172|21|771|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-173|21|773|Neoplasia malignant|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-174|21|773|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-175|21|776|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-176|21|777|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-177|21|778|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-178|21|778|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-179|21|778|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-180|21|780|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-181|21|780|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-182|21|780|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-183|21|782|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-184|21|786|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-185|21|786|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-186|21|789|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-187|21|792|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-188|21|792|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-189|21|794|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-190|21|795|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-191|21|796|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-192|21|799|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-193|21|800|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-194|21|801|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-195|21|802|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-196|21|806|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-197|21|806|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-198|21|807|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-199|21|808|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-200|21|809|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-201|21|813|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-202|21|814|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-203|21|814|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-204|21|815|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-205|21|815|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-206|21|816|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-207|21|817|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-208|21|817|Neoplasia unclassified|Reproductive system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-209|21|818|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-210|21|827|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-211|21|828|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-212|21|829|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-213|21|830|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-214|21|830|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-215|21|831|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-216|21|834|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-217|21|835|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-218|21|836|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|metastatic,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-219|21|837|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-220|21|840|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-221|21|841|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-222|21|842|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-223|21|843|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-224|21|844|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-225|21|848|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-226|21|849|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-227|21|850|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-228|21|850|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-229|21|850|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-230|21|851|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-231|21|851|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-232|21|854|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-233|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-234|21|855|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-235|21|855|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000565 - mesothelium|,MPATH: 365 - mesothelioma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-236|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-237|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-238|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-239|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-240|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-241|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-242|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-243|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-244|21|855|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-245|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-246|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-247|21|855|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-248|21|855|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-249|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-250|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-251|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-252|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-253|21|855|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-254|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-255|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-256|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-257|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-258|21|855|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-259|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-260|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-261|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-262|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-263|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-264|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-265|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-266|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-267|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-268|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-269|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-270|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-271|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-272|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-273|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-274|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-275|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-276|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-277|21|855|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-278|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-279|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-280|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-281|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-282|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-283|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-284|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-285|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-286|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-287|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-288|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-289|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-290|21|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-291|21|856|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-292|21|857|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-293|21|858|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-294|21|859|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-295|21|859|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-296|21|862|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-297|21|864|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-298|21|866|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-299|21|869|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-300|21|870|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-301|21|873|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-302|21|876|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-303|21|877|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-304|21|879|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-305|21|880|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-306|21|881|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-307|21|885|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-308|21|885|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-309|21|886|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-310|21|887|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-311|21|887|Neoplasia unclassified|Reproductive system|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-312|21|894|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-313|21|898|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-314|21|900|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-315|21|900|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-316|21|900|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-317|21|901|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-318|21|901|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-319|21|905|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-320|21|911|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-321|21|911|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-322|21|914|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-323|21|918|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-324|21|920|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-325|21|920|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-326|21|920|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-327|21|921|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-328|21|922|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-329|21|924|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-330|21|926|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-331|21|927|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-332|21|932|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-333|21|933|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-334|21|934|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-335|21|935|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-336|21|936|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-337|21|939|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-338|21|941|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-339|21|942|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-340|21|942|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-341|21|946|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-342|21|946|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-343|21|947|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-344|21|948|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-345|21|949|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-346|21|949|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-347|21|949|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-348|21|950|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-349|21|950|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-350|21|953|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-351|21|954|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-352|21|960|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-353|21|960|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-354|21|961|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-355|21|962|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-356|21|963|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 219 - adnexal and skin appendage tumor|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-357|21|963|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-358|21|963|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-359|21|963|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-360|21|967|Neoplasia benign|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-361|21|969|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-362|21|970|Neoplasia malignant|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-363|21|970|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-364|21|973|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-365|21|974|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-366|21|975|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-367|21|975|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-368|21|976|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-369|21|977|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-370|21|977|Hyperplastic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-371|21|979|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-372|21|981|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-373|21|981|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-374|21|986|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-375|21|987|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-376|21|988|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-377|21|988|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-378|21|988|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-379|21|988|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-380|21|991|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-381|21|992|Other deterministic changes|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-382|21|992|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-383|21|992|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-384|21|993|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-385|21|993|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-386|21|995|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-387|21|995|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|metastatic lung tumour,MPATH: 212 - inflammation|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-388|21|996|Neoplasia malignant|Lower respiratory system|n/a|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-389|21|997|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-390|21|997|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-391|21|997|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-21|NESI-Gy 0.6,88-90|1|92|neutrons fission|0.6|grays|External exposure|Silene|392 (392 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|were 239 animals before check contains perhaps 2 previous groups|2-12-21-392|21|999|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-1|22|225|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-2|22|233|Other deterministic changes|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-3|22|271|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-4|22|299|Other deterministic changes|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-5|22|307|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-6|22|307|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-7|22|307|Other deterministic changes|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-8|22|330|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-9|22|389|Other deterministic changes|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-10|22|390|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-11|22|393|Neoplasia benign|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-12|22|426|Other deterministic changes|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-13|22|429|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-14|22|435|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-15|22|439|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-16|22|444|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-17|22|453|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-18|22|459|Other deterministic changes|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-19|22|480|Other deterministic changes|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-20|22|492|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-21|22|492|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-22|22|495|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-23|22|495|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-24|22|518|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-25|22|523|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-26|22|528|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-27|22|538|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-28|22|545|Neoplasia malignant|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-29|22|552|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-30|22|556|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-31|22|559|Neoplasia malignant|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-32|22|559|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-33|22|566|Neoplasia malignant|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-34|22|572|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-35|22|579|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-36|22|592|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-37|22|596|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-38|22|597|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-39|22|597|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-40|22|601|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-41|22|604|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-42|22|605|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-43|22|607|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-44|22|607|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-45|22|609|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-46|22|609|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-47|22|612|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-48|22|616|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-49|22|618|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-50|22|629|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-51|22|629|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-52|22|629|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-53|22|633|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-54|22|633|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-55|22|634|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-56|22|636|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-57|22|636|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-58|22|636|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-59|22|639|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-60|22|653|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-61|22|656|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-62|22|660|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-63|22|660|Neoplasia malignant|Lower respiratory system|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-64|22|663|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-65|22|673|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-66|22|674|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-67|22|678|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-68|22|681|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-69|22|682|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 409 - fibrous histiocytoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-70|22|685|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-71|22|689|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-72|22|704|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-73|22|704|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-74|22|708|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-75|22|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-76|22|740|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-77|22|740|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-78|22|758|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-79|22|796|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-22|NESI-Gy 1.15,11/83|1|92|neutrons fission|1.15|grays|External exposure|Silene|80 (80 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-22-80|22|816|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-1|23|195|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-2|23|255|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|metastatic,MPATH: 551 - sarcoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-3|23|275|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-4|23|277|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-5|23|280|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-6|23|297|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-7|23|298|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-8|23|301|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-9|23|305|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-10|23|317|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-11|23|323|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-12|23|342|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-13|23|347|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-14|23|358|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-15|23|358|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-16|23|363|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-17|23|376|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-18|23|382|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-19|23|383|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|benign,MPATH: 513 - Lymphoid neoplasms|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-20|23|384|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|metastatic,MPATH: 218 - neoplasm|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-21|23|384|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-22|23|385|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-23|23|385|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-24|23|386|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-25|23|386|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-26|23|400|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-27|23|400|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-28|23|431|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-29|23|434|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-30|23|435|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-31|23|438|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-32|23|438|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-33|23|440|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-34|23|449|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-35|23|469|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-36|23|477|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-37|23|485|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-38|23|541|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-39|23|545|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-40|23|545|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-41|23|556|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-42|23|559|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-43|23|560|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-44|23|593|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-45|23|595|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-46|23|601|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-47|23|622|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-48|23|649|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-49|23|653|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-23|NESI-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-23-50|23|657|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-1|24|180|Other deterministic changes|Lower respiratory system|n/a|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-2|24|227|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-3|24|283|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-4|24|294|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-5|24|309|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-6|24|343|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-7|24|367|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-8|24|419|Other deterministic changes|Lower respiratory system|n/a|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-9|24|430|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-10|24|431|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-11|24|432|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-12|24|441|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-13|24|454|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-14|24|454|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|metastatic,MPATH: 551 - sarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-15|24|461|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-16|24|469|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-17|24|480|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-18|24|483|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-19|24|483|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-20|24|494|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-21|24|512|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-22|24|515|Neoplasia malignant|Lower respiratory system|n/a|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-23|24|515|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-24|24|539|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-25|24|546|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-26|24|551|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-27|24|551|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-28|24|551|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-29|24|559|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-30|24|567|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-31|24|567|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 551 - sarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-32|24|583|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-33|24|595|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-34|24|598|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-35|24|602|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-36|24|602|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-37|24|610|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-38|24|634|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-39|24|636|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-24|NESI-Gy 1.73,11/83|1|92|neutrons fission|1.73|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-24-40|24|692|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-1|25|7|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-2|25|7|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-3|25|235|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-4|25|244|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-5|25|245|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-6|25|281|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-7|25|301|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-8|25|310|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-9|25|350|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-10|25|350|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-11|25|359|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-12|25|359|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-13|25|366|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-14|25|367|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-15|25|369|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-16|25|371|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-17|25|373|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-18|25|373|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-19|25|379|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-20|25|385|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-21|25|386|Neoplasia malignant|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-22|25|412|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-23|25|422|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-24|25|426|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-25|25|430|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-26|25|436|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-27|25|451|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-28|25|451|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-29|25|454|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-30|25|461|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-31|25|465|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-32|25|470|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-33|25|471|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-34|25|478|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-35|25|485|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-36|25|486|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-37|25|486|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-38|25|491|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-39|25|496|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-40|25|496|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-41|25|496|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-42|25|505|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-43|25|505|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-44|25|505|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-45|25|505|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-46|25|505|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-47|25|506|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-48|25|507|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-49|25|512|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-50|25|512|Neoplasia benign|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-51|25|520|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-52|25|520|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-53|25|520|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-54|25|527|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-55|25|527|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-56|25|529|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-57|25|531|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-58|25|532|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-59|25|533|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-60|25|533|Neoplasia malignant|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-61|25|539|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-62|25|539|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-63|25|539|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-64|25|545|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-65|25|545|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-66|25|546|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-67|25|546|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-68|25|555|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-69|25|555|Neoplasia malignant|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-70|25|555|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-71|25|555|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-72|25|562|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-73|25|562|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-74|25|562|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-75|25|562|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-76|25|562|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-77|25|566|Neoplasia malignant|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-78|25|568|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-79|25|570|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-80|25|574|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-81|25|575|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-82|25|576|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-83|25|576|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-84|25|576|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-85|25|576|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-86|25|576|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-87|25|581|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-88|25|589|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-89|25|591|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-90|25|595|Other deterministic changes|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-91|25|595|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-92|25|595|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-93|25|604|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-94|25|604|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-95|25|604|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-96|25|608|Neoplasia benign|Lower respiratory system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-97|25|609|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-98|25|617|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-99|25|624|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-100|25|624|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-101|25|624|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-102|25|626|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-103|25|639|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-104|25|639|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 551 - sarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-105|25|654|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-106|25|654|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-107|25|659|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-108|25|675|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-109|25|675|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-110|25|678|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-111|25|687|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-112|25|693|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-113|25|693|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-114|25|693|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-115|25|696|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-116|25|696|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-117|25|700|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-118|25|700|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-119|25|701|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-12-25|NESI-Gy 2,10/78|1|92|neutrons fission|2|grays|External exposure|Silene|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-25-120|25|701|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-1|26|51|Other deterministic changes|Lower respiratory system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-2|26|199|Other deterministic changes|Lower respiratory system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-3|26|351|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-4|26|351|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-5|26|361|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-6|26|376|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-7|26|385|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-8|26|386|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-9|26|397|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-10|26|420|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-11|26|427|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|metastatic,MPATH: 242 - hemangiosarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-12|26|446|Other deterministic changes|Lower respiratory system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-13|26|450|Other deterministic changes|Lower respiratory system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-14|26|460|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|,MPATH: 365 - mesothelioma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-15|26|468|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-16|26|482|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-17|26|489|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-18|26|510|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-19|26|513|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-20|26|517|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-21|26|517|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-22|26|524|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-23|26|524|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-24|26|527|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-25|26|530|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-26|26|530|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-27|26|538|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-28|26|543|Other deterministic changes|Lower respiratory system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-29|26|548|Other deterministic changes|Lower respiratory system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-30|26|565|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-31|26|569|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-32|26|576|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-33|26|577|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-34|26|584|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-35|26|635|Other deterministic changes|Lower respiratory system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-36|26|643|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 409 - fibrous histiocytoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-37|26|650|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-38|26|660|Other deterministic changes|Lower respiratory system|n/a|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-39|26|669|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-26|NESI-Gy 2.86,10/78|1|92|neutrons fission|2.86|grays|External exposure|Silene|40 (40 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-26-40|26|685|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-1|27|44|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-2|27|69|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-3|27|70|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-4|27|70|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-5|27|71|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-6|27|71|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-7|27|309|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-8|27|309|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-9|27|329|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-10|27|336|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-11|27|336|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 219 - adnexal and skin appendage tumor|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-12|27|337|Neoplasia benign|Lower respiratory system,MA: 0000415 - lung|,MPATH: 240 - hemangioma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-13|27|345|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-14|27|345|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-15|27|345|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-16|27|352|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-17|27|352|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-18|27|352|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-19|27|363|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-20|27|374|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-21|27|381|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-22|27|395|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-23|27|405|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-24|27|416|Neoplasia malignant|Liver among hepato-pancreatic system diseases|benign|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-25|27|422|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-26|27|428|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-27|27|428|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-28|27|428|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-29|27|435|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-30|27|447|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-31|27|453|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-32|27|456|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-33|27|463|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-34|27|463|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-35|27|476|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-36|27|489|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-37|27|489|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-38|27|489|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-39|27|492|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-40|27|492|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-41|27|492|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-42|27|512|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-43|27|512|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-44|27|520|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-45|27|523|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-46|27|530|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-47|27|534|Neoplasia benign|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-48|27|534|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-49|27|541|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-50|27|547|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-51|27|582|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-52|27|588|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-53|27|593|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-54|27|606|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-55|27|641|Other deterministic changes|Lower respiratory system|n/a|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-56|27|644|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-57|27|644|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-27|NEOR-Gy 4,5/83|1|92|neutrons 1-10 MeV|4|grays|External exposure|whole body 8 Gy/min 1-30 MeV|58 (58 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-27-58|27|644|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|metastatic,MPATH: 551 - sarcoma|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-1|28|314|Other deterministic changes|Whole body|n/a|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-2|28|480|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-3|28|483|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-4|28|533|Hyperplastic changes|Lower respiratory system|n/a|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-5|28|545|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-6|28|545|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-7|28|554|Neoplasia unclassified|Reproductive system|n/a|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-8|28|580|Other deterministic changes|Whole body|n/a|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-9|28|607|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-10|28|613|Hyperplastic changes|Lower respiratory system|n/a|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-11|28|634|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-28|ALSA-Gy 5,5/74|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-28-12|28|634|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-1|29|173|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-2|29|358|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-3|29|361|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-4|29|375|Other deterministic changes|Whole body|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-5|29|398|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-6|29|399|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|,MPATH: 322 - teratoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-7|29|426|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-8|29|525|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-9|29|525|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-10|29|575|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-11|29|576|Other deterministic changes|Lower respiratory system|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-12|29|579|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-13|29|585|Other deterministic changes|Lower respiratory system|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-14|29|600|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-15|29|601|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-16|29|612|Other deterministic changes|Lower respiratory system|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-17|29|634|Other deterministic changes|Lower respiratory system|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-18|29|638|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-19|29|638|Neoplasia malignant|Lower respiratory system|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-20|29|644|Other deterministic changes|Lower respiratory system|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-21|29|645|Neoplasia benign|Lower respiratory system|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-22|29|645|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-23|29|645|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-24|29|645|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-25|29|645|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-26|29|652|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-27|29|652|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-28|29|652|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-29|29|659|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-30|29|673|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-31|29|686|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-32|29|715|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-33|29|722|Hyperplastic changes|Lower respiratory system|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-34|29|736|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-35|29|739|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-29|ALSA-Gy 7.5,76-77|1|92|accel. alpha whole body|7.5|grays|External exposure|whole body 500 MeV Saturne|36 (36 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-29-36|29|771|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-1|30|349|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-2|30|372|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-3|30|377|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-4|30|394|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|benign,MPATH: 242 - hemangiosarcoma|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-5|30|398|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-6|30|416|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-7|30|418|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-8|30|418|Other deterministic changes|Lower respiratory system|n/a|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-9|30|429|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-10|30|440|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-11|30|441|Other deterministic changes|Whole body|n/a|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-12|30|454|Other deterministic changes|Lower respiratory system|n/a|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-13|30|461|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-14|30|463|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-15|30|492|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-16|30|492|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-17|30|498|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-18|30|499|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-19|30|499|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-20|30|504|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-21|30|504|Other deterministic changes|Lower respiratory system|n/a|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-22|30|513|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-23|30|513|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-30|ALSAa-Gy 7.5,1/77|1|92|accel. alpha local|7.5|grays|External exposure local|abdomen 500 MeV Saturne|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-30-24|30|517|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-1|31|479|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-2|31|480|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|benign,MPATH: 446 - squamous cell carcinoma|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-3|31|490|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-4|31|521|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-5|31|595|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-6|31|612|Other deterministic changes|Lower respiratory system|n/a|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-7|31|634|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-8|31|646|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-9|31|653|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-10|31|686|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-31|ALSA-Gy 10,5/74|1|92|accel. alpha whole body|10|grays|External exposure|whole body 500 MeV Saturne|11 (11 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-31-11|31|707|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-1|32|15|Other deterministic changes|Whole body|n/a|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-2|32|80|Other deterministic changes|Lower respiratory system|n/a|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-3|32|258|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-4|32|290|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-5|32|290|Neoplasia malignant|Heart among cardiovascular system,MA: 0000072 - heart|,MPATH: 511 - Myeloproliferation (genetic)|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-6|32|326|Neoplasia malignant|Liver among hepato-pancreatic system diseases|benign|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-7|32|347|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-8|32|348|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-9|32|354|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-10|32|363|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-11|32|393|Other deterministic changes|Lower respiratory system|n/a|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-12|32|395|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-13|32|408|Hyperplastic changes|Lower respiratory system|n/a|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-14|32|432|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-15|32|445|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-16|32|455|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-17|32|461|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-18|32|461|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-19|32|465|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-20|32|469|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-21|32|484|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-22|32|490|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-23|32|517|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-24|32|517|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-25|32|531|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-26|32|531|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-27|32|532|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-28|32|538|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-29|32|550|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-30|32|551|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-31|32|586|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-32|32|609|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-33|32|613|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-32|ALSA-Gy 15,75|1|92|accel. alpha whole body|15|grays|External exposure|whole body 500 MeV Saturne|34 (34 in ERA)|Rat|Rat, Sprague-Dawley SPF|Both|Young Adult|lifespan study|2-12-32-34|32|615|Neoplasia malignant|Liver among hepato-pancreatic system diseases|benign|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-1|33|277|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-2|33|305|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-3|33|316|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-4|33|350|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-5|33|394|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-6|33|394|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-7|33|415|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-8|33|512|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|,MPATH: 322 - teratoma|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-9|33|526|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-33|ALSAGy 20-,2/75|1|92|accel. alpha whole body|20|grays|External exposure|whole body 500 MeV Saturne|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-33-10|33|526|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-34|ALSA-Gy 25,2/75|1|92|accel. alpha whole body|25|grays|External exposure|whole body 500 MeV Saturne|9 (9 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-34-1|34|285|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-34|ALSA-Gy 25,2/75|1|92|accel. alpha whole body|25|grays|External exposure|whole body 500 MeV Saturne|9 (9 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-34-2|34|285|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-34|ALSA-Gy 25,2/75|1|92|accel. alpha whole body|25|grays|External exposure|whole body 500 MeV Saturne|9 (9 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-34-3|34|285|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-34|ALSA-Gy 25,2/75|1|92|accel. alpha whole body|25|grays|External exposure|whole body 500 MeV Saturne|9 (9 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-34-4|34|285|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-12-34|ALSA-Gy 25,2/75|1|92|accel. alpha whole body|25|grays|External exposure|whole body 500 MeV Saturne|9 (9 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-34-5|34|286|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-34|ALSA-Gy 25,2/75|1|92|accel. alpha whole body|25|grays|External exposure|whole body 500 MeV Saturne|9 (9 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-34-6|34|304|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-34|ALSA-Gy 25,2/75|1|92|accel. alpha whole body|25|grays|External exposure|whole body 500 MeV Saturne|9 (9 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-34-7|34|331|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-12-34|ALSA-Gy 25,2/75|1|92|accel. alpha whole body|25|grays|External exposure|whole body 500 MeV Saturne|9 (9 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-34-8|34|440|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-34|ALSA-Gy 25,2/75|1|92|accel. alpha whole body|25|grays|External exposure|whole body 500 MeV Saturne|9 (9 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-34-9|34|534|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-35|ALSA-BNF-Gy 5,5/85|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-1|35|26|Other deterministic changes|Lower respiratory system|n/a|
2-12-35|ALSA-BNF-Gy 5,5/85|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-2|35|45|Other deterministic changes|Lower respiratory system|n/a|
2-12-35|ALSA-BNF-Gy 5,5/85|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-3|35|65|Other deterministic changes|Lower respiratory system|n/a|
2-12-35|ALSA-BNF-Gy 5,5/85|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-4|35|65|Other deterministic changes|Lower respiratory system|n/a|
2-12-35|ALSA-BNF-Gy 5,5/85|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-5|35|187|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-35|ALSA-BNF-Gy 5,5/85|1|92|accel. alpha whole body|5|grays|External exposure|whole body 500 MeV Saturne|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-6|35|195|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-35|ALSA-BNF-Gy 5,5/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-1|35|26|Other deterministic changes|Lower respiratory system|n/a|
2-12-35|ALSA-BNF-Gy 5,5/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-2|35|45|Other deterministic changes|Lower respiratory system|n/a|
2-12-35|ALSA-BNF-Gy 5,5/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-3|35|65|Other deterministic changes|Lower respiratory system|n/a|
2-12-35|ALSA-BNF-Gy 5,5/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-4|35|65|Other deterministic changes|Lower respiratory system|n/a|
2-12-35|ALSA-BNF-Gy 5,5/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-5|35|187|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-35|ALSA-BNF-Gy 5,5/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|6 (6 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-35-6|35|195|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-1|36|96|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-2|36|124|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-3|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-4|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-5|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-6|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-7|36|152|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-8|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-9|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-10|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-11|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-12|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-1|36|96|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-2|36|124|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-3|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-4|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-5|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-6|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-7|36|152|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-8|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-9|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-10|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-11|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-36|ALSA-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-36-12|36|152|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-1|37|6|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-2|37|75|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-3|37|81|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-4|37|82|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-5|37|82|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-6|37|89|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-7|37|127|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-8|37|150|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-9|37|156|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-10|37|156|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-11|37|166|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|1|92|accel. alpha local|3.7|grays|External exposure local|30 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-12|37|166|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-1|37|6|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-2|37|75|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-3|37|81|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-4|37|82|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-5|37|82|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-6|37|89|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-7|37|127|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-8|37|150|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-9|37|156|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-10|37|156|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-11|37|166|Other deterministic changes|Lower respiratory system|n/a|
2-12-37|ALSA*-BN-Gy 3.7,10/85|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-37-12|37|166|Other deterministic changes|Lower respiratory system|n/a|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-1|38|3|Other deterministic changes|Lower respiratory system|n/a|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-2|38|83|Other deterministic changes|Lower respiratory system|n/a|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-3|38|88|Other deterministic changes|Lower respiratory system|n/a|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-4|38|135|Other deterministic changes|Lower respiratory system|n/a|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-5|38|143|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-6|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-7|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-8|38|150|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-9|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-10|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-11|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|1|92|accel. alpha local|11.6|grays|External exposure local|10 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-12|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-1|38|3|Other deterministic changes|Lower respiratory system|n/a|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-2|38|83|Other deterministic changes|Lower respiratory system|n/a|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-3|38|88|Other deterministic changes|Lower respiratory system|n/a|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-4|38|135|Other deterministic changes|Lower respiratory system|n/a|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-5|38|143|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-6|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-7|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-8|38|150|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-9|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-10|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-11|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-38|ALSA-BN-Gy 11.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-38-12|38|150|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-1|39|6|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-2|39|6|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-3|39|81|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-4|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-5|39|151|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-6|39|151|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-7|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-8|39|151|Hyperplastic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-9|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-10|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-11|39|151|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|1|92|accel. alpha local|18.4|grays|External exposure local|5.2 mm collim. on abdomen|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-12|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-1|39|6|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-2|39|6|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-3|39|81|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-4|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-5|39|151|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-6|39|151|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-7|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-8|39|151|Hyperplastic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-9|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-10|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-11|39|151|Other deterministic changes|Lower respiratory system|n/a|
2-12-39|ALSA-BN-Gy 18.4,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|12 (12 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-39-12|39|151|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-1|40|136|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-2|40|147|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-3|40|148|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-4|40|149|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-5|40|155|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-6|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-7|40|162|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-8|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-9|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-10|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-11|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-12|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-13|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-14|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-15|40|162|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-16|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-17|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-18|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-19|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-20|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-21|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-22|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-23|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|1|92|accel. alpha local|44.6|grays|External exposure local|3 mm collim. on abdomen|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-24|40|162|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-1|40|136|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-2|40|147|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-3|40|148|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-4|40|149|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-5|40|155|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-6|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-7|40|162|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-8|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-9|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-10|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-11|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-12|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-13|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-14|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-15|40|162|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-16|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-17|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-18|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-19|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-20|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-21|40|162|Other deterministic changes|Lower respiratory system|n/a|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-22|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-23|40|162|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-40|ALSA-BN-Gy 44.6,4/84|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-40-24|40|162|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-1|41|36|Other deterministic changes|Whole body|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-2|41|162|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-3|41|221|Other deterministic changes|Whole body|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-4|41|243|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-5|41|255|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-6|41|263|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-7|41|284|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-8|41|382|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-9|41|451|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-10|41|451|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-11|41|456|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-12|41|473|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-13|41|491|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-14|41|492|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-15|41|493|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-16|41|508|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-17|41|527|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-18|41|528|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-19|41|542|Hyperplastic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-20|41|555|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|,MPATH: 446 - squamous cell carcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-21|41|567|Neoplasia benign|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-22|41|589|Other deterministic changes|Whole body|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-23|41|595|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-24|41|606|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-25|41|606|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-26|41|631|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-27|41|631|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-28|41|634|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-29|41|653|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-30|41|655|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-31|41|655|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-32|41|669|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-33|41|675|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-34|41|683|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-35|41|718|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-36|41|718|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-37|41|718|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-38|41|722|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-39|41|724|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-40|41|731|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-41|41|743|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-42|41|752|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-43|41|754|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-44|41|764|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-45|41|771|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-46|41|781|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-47|41|789|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-48|41|796|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-49|41|799|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-50|41|803|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-51|41|808|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-52|41|815|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 242 - hemangiosarcoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-53|41|821|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-54|41|839|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-55|41|850|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-56|41|880|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 551 - sarcoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-57|41|928|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-58|41|936|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-59|41|948|Other deterministic changes|Lower respiratory system|n/a|
2-12-41|GaTH-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-41-60|41|950|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-1|42|165|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-2|42|165|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-3|42|278|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-4|42|278|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-5|42|437|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-6|42|437|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-7|42|509|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-8|42|509|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-9|42|509|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-10|42|568|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-11|42|570|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-12|42|570|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-42|GaTH-BN-Gy 2.5,12/79|1|92|Bremsstrahlung > 3MeV.|2.5|grays|External exposure|mean dose (1.5-3.5 Gy) from Thalie|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-13|42|570|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-1|42|165|Preneoplastic changes|Lower respiratory system,MA: 0000422 - bronchiole|,MPATH: 171 - squamous metaplasia|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-2|42|165|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-3|42|278|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-4|42|278|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-5|42|437|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-6|42|437|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-7|42|509|Other deterministic changes|Other local manifestations and miscellaneus|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-8|42|509|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-9|42|509|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-10|42|568|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-11|42|570|Other deterministic changes|Lower respiratory system|n/a|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-12|42|570|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-42|GaTH-BN-Gy 2.5,12/79|2|92|BNF -naphtoflavone|25|milligrams per kg animal|Injection, intramuscular|6 IM inject. 15d interval|13 (13 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-42-13|42|570|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-1|43|2|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-2|43|259|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-3|43|337|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-4|43|381|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-5|43|425|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-6|43|444|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-7|43|458|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-8|43|473|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-9|43|483|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-10|43|525|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-11|43|529|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-12|43|532|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-13|43|535|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-14|43|548|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-15|43|556|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-16|43|580|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-17|43|585|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-18|43|644|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-19|43|648|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-20|43|671|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-21|43|688|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-22|43|688|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-23|43|703|Other deterministic changes|Lower respiratory system|n/a|
2-12-43|NECf-Gy 3.5,2/77|1|92|neutrons C-252|3.5|grays|External exposure local|hindpaw 38.2 mGy/h|24 (24 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-43-24|43|703|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-1|44|142|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-2|44|209|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-3|44|263|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-4|44|320|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-5|44|357|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-6|44|362|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-7|44|391|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-8|44|410|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-9|44|421|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-10|44|423|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-11|44|444|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-12|44|447|Hyperplastic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-13|44|475|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-14|44|480|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-15|44|498|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-16|44|505|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-17|44|510|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-18|44|523|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-19|44|529|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-20|44|543|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-21|44|545|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-22|44|549|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-23|44|554|Hyperplastic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-24|44|565|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-25|44|569|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-26|44|587|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-27|44|608|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-28|44|616|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-29|44|620|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-30|44|633|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-31|44|635|Other deterministic changes|Lower respiratory system|n/a|
2-12-44|NECf-Gy 8,6/77|1|92|neutrons C-252|8|grays|External exposure local|lumbar region 45 mGy/h|32 (32 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-44-32|44|650|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-1|45|241|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-2|45|261|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-3|45|277|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-4|45|288|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-5|45|379|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-6|45|435|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-7|45|458|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-8|45|470|Other deterministic changes|Lower respiratory system|n/a|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-9|45|476|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-10|45|531|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-11|45|550|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-12|45|554|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-13|45|564|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-14|45|568|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-15|45|612|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-16|45|621|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-17|45|647|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-18|45|660|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-19|45|684|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-20|45|684|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-21|45|691|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-22|45|694|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-45|NECfw-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h|23 (23 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-45-23|45|694|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-1|46|413|Other deterministic changes|Lower respiratory system|n/a|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-2|46|435|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-3|46|488|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-4|46|496|Other deterministic changes|Lower respiratory system|n/a|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-5|46|503|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-6|46|520|Other deterministic changes|Lower respiratory system|n/a|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-7|46|543|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-8|46|545|Neoplasia malignant|Reproductive system,MA: 0000404 - prostate gland|,MPATH: 268 - adenocarcinoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-9|46|545|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-10|46|550|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-11|46|563|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-12|46|563|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-13|46|563|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-14|46|599|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-15|46|603|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-16|46|603|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-17|46|612|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-18|46|627|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-19|46|633|Other deterministic changes|Lower respiratory system|n/a|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-20|46|646|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-21|46|662|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-46|NECfwc-Gy 2,8/84|1|92|neutrons C-252|2|grays|External exposure|whole body 4 mGy/h anti-cataract treatment|22 (22 in ERA)|Rat|Rat Wistar|Male|Young Adult|lifespan study|2-12-46-22|46|690|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-1|47|3060|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-2|47|310|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-3|47|370|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-4|47|371|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-5|47|426|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-6|47|460|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-7|47|470|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-8|47|477|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-9|47|483|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-10|47|488|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-11|47|499|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-12|47|500|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-13|47|501|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-14|47|503|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-15|47|506|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-16|47|506|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-17|47|507|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-18|47|516|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-19|47|521|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-20|47|522|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-21|47|524|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-22|47|538|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-23|47|539|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-24|47|543|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-25|47|544|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-26|47|545|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-27|47|549|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-28|47|549|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-29|47|550|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-30|47|550|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-31|47|551|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-32|47|551|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-33|47|566|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-34|47|572|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-35|47|574|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-36|47|577|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-37|47|577|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-38|47|578|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-39|47|580|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-40|47|584|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-41|47|584|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-42|47|584|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-43|47|587|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-44|47|588|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-45|47|588|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-46|47|588|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-47|47|592|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-48|47|595|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-49|47|600|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-50|47|601|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-51|47|602|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-52|47|602|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-53|47|608|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-54|47|615|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-55|47|619|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-56|47|619|Neoplasia benign|Bloodvessels among cardiovascular system|metastatic|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-57|47|623|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-58|47|632|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-59|47|632|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-60|47|634|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-61|47|637|Neoplasia benign|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-62|47|638|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-63|47|646|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-64|47|649|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|benign,MPATH: 219 - adnexal and skin appendage tumor|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-65|47|649|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-66|47|654|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-67|47|659|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-68|47|657|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-69|47|662|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-70|47|662|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-71|47|662|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-72|47|663|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-73|47|663|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-74|47|667|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-75|47|667|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-76|47|673|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-77|47|673|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-78|47|671|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-79|47|675|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-80|47|675|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-81|47|676|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-82|47|681|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-83|47|682|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-84|47|682|Neoplasia benign|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-85|47|687|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-86|47|685|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-87|47|691|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-88|47|691|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-89|47|695|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-90|47|696|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-91|47|696|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-92|47|698|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-93|47|701|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-94|47|701|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-95|47|703|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-96|47|703|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-97|47|704|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-98|47|708|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-99|47|709|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-100|47|710|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-101|47|710|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-102|47|717|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-103|47|717|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-104|47|718|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-105|47|718|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-106|47|722|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-107|47|722|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-108|47|724|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-109|47|724|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-110|47|725|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-111|47|729|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-112|47|729|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-113|47|729|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-114|47|731|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-115|47|731|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-116|47|733|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-117|47|733|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-118|47|736|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-119|47|734|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-120|47|737|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-121|47|740|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-122|47|740|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-123|47|743|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-124|47|743|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-125|47|744|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-126|47|745|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-127|47|750|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-128|47|753|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-129|47|753|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-130|47|754|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-131|47|754|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-132|47|754|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-133|47|755|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-134|47|760|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-135|47|764|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-136|47|764|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-137|47|764|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-138|47|765|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-139|47|765|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-140|47|773|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-141|47|774|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-142|47|775|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-143|47|778|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-144|47|778|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-145|47|785|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-146|47|786|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 551 - sarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-147|47|786|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-148|47|788|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-149|47|792|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-150|47|792|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-151|47|792|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-152|47|792|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-153|47|793|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-154|47|794|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-155|47|795|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-156|47|796|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-157|47|799|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-158|47|799|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-159|47|801|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-160|47|801|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-161|47|803|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-162|47|806|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-163|47|806|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-164|47|806|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-165|47|807|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-166|47|808|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-167|47|809|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-168|47|813|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-169|47|813|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-170|47|814|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-171|47|816|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-172|47|820|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-173|47|820|Neoplasia benign|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-174|47|821|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-175|47|821|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-176|47|822|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-177|47|828|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-178|47|829|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-179|47|831|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-180|47|834|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-181|47|834|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-182|47|835|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-183|47|835|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-184|47|836|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-185|47|837|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-186|47|838|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-187|47|838|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-188|47|838|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-189|47|838|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-190|47|841|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-191|47|842|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-192|47|842|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-193|47|842|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-194|47|843|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-195|47|843|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-196|47|849|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-197|47|849|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-198|47|849|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-199|47|852|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-200|47|852|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-201|47|855|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-202|47|855|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-203|47|856|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-204|47|857|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|metastatic,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-205|47|857|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-206|47|858|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-207|47|858|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-208|47|859|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-209|47|859|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-210|47|859|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-211|47|859|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-212|47|862|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-213|47|862|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-214|47|865|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-215|47|866|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-216|47|866|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-217|47|869|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-218|47|869|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-219|47|869|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-220|47|871|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-221|47|873|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-222|47|873|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-223|47|876|Neoplasia malignant|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-224|47|876|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-225|47|876|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-226|47|876|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-227|47|880|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-228|47|883|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-229|47|883|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-230|47|883|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-231|47|884|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-232|47|886|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-233|47|886|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-234|47|890|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-235|47|890|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-236|47|892|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-237|47|892|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-238|47|897|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-239|47|897|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-240|47|898|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-241|47|904|Hyperplastic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-242|47|904|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-243|47|905|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-244|47|905|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-245|47|911|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-246|47|911|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-247|47|911|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-248|47|914|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-249|47|914|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-250|47|915|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-251|47|915|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-252|47|915|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-253|47|918|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-254|47|920|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-255|47|922|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-256|47|925|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-257|47|929|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-258|47|929|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-259|47|932|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-260|47|932|Neoplasia malignant|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-261|47|932|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-262|47|934|Neoplasia malignant|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-263|47|934|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-264|47|936|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-265|47|943|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-266|47|943|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-267|47|946|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-268|47|948|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-269|47|949|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-270|47|950|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-271|47|950|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-272|47|953|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-273|47|955|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-274|47|957|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-275|47|958|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-276|47|966|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-277|47|966|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-278|47|973|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-279|47|974|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-280|47|976|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-281|47|979|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-282|47|981|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-283|47|985|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-284|47|983|Neoplasia benign|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-285|47|996|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-286|47|999|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-287|47|999|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-288|47|1008|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-289|47|1020|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-290|47|1018|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-291|47|1022|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-292|47|1034|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-293|47|1035|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-294|47|1038|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-295|47|1044|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-296|47|1050|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-297|47|1057|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-298|47|1078|Neoplasia malignant|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-299|47|1079|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-300|47|126|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-301|47|194|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-302|47|278|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-303|47|290|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-304|47|341|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-305|47|366|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-306|47|425|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-307|47|432|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-308|47|434|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-309|47|442|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-310|47|450|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-311|47|453|Neoplasia unclassified|Lower respiratory system,MA: 0000032 - thoracic cavity|,MPATH: 238 - hemangioblastoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-312|47|455|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-313|47|455|Neoplasia benign|Bloodvessels among cardiovascular system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-314|47|460|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-315|47|464|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-316|47|486|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-317|47|504|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-318|47|504|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-319|47|509|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-320|47|512|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-321|47|531|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-322|47|532|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-323|47|537|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-324|47|540|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-325|47|541|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-326|47|545|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-327|47|547|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-328|47|558|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-329|47|561|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 409 - fibrous histiocytoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-330|47|580|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-331|47|582|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-332|47|582|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-333|47|586|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-334|47|586|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-335|47|597|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-336|47|597|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-337|47|600|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-338|47|604|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-339|47|604|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-340|47|605|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-341|47|623|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-342|47|628|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-343|47|629|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 426 - leiomyosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-344|47|632|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-345|47|635|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-346|47|636|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-347|47|638|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-348|47|649|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-349|47|649|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-350|47|649|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-351|47|7|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-352|47|7|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-353|47|651|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-354|47|655|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-355|47|657|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-356|47|662|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-357|47|662|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-358|47|666|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-359|47|671|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-360|47|678|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-361|47|680|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-362|47|683|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-363|47|683|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-364|47|685|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-365|47|685|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-366|47|685|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-367|47|685|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-368|47|686|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-369|47|687|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-370|47|690|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-371|47|692|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-372|47|698|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-373|47|698|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-374|47|699|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-375|47|699|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-376|47|701|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-377|47|702|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-378|47|702|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-379|47|708|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-380|47|709|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-381|47|712|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-382|47|712|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-383|47|713|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|benign,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-384|47|713|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-385|47|714|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-386|47|722|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-387|47|726|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-388|47|727|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-389|47|727|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-390|47|727|Neoplasia malignant|Adrenal gland  among endocrine systems|metastatic|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-391|47|727|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-392|47|728|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-393|47|732|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-394|47|732|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-395|47|732|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-396|47|732|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-397|47|736|Neoplasia benign|Lower respiratory system,MA: 0000415 - lung|,MPATH: 240 - hemangioma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-398|47|736|Neoplasia malignant|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-399|47|739|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-400|47|746|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-401|47|753|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-402|47|749|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-403|47|749|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-404|47|7|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-405|47|7|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-406|47|749|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-407|47|761|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-408|47|761|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-409|47|761|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-410|47|763|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-411|47|764|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|metastatic lung tumour,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-412|47|767|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-413|47|769|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-414|47|771|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-415|47|774|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-416|47|774|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-417|47|774|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-418|47|776|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-419|47|776|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-420|47|777|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-421|47|781|Neoplasia malignant|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-422|47|781|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-423|47|788|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-424|47|788|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-425|47|789|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-426|47|790|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-427|47|792|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-428|47|795|Neoplasia unclassified|Reproductive system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-429|47|795|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-430|47|796|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-431|47|796|Hyperplastic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-432|47|793|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-433|47|797|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-434|47|798|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-435|47|798|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-436|47|799|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-437|47|799|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-438|47|802|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-439|47|802|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-440|47|803|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-441|47|803|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-442|47|803|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-443|47|811|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-444|47|813|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-445|47|813|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-446|47|816|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-447|47|816|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-448|47|816|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-449|47|825|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-450|47|830|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-451|47|830|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-452|47|833|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-453|47|833|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-454|47|834|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-455|47|837|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-456|47|837|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-457|47|7|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-458|47|7|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-459|47|838|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-460|47|841|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-461|47|841|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-462|47|844|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-463|47|844|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-464|47|842|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-465|47|846|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-466|47|846|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-467|47|848|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-468|47|848|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-469|47|852|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-470|47|852|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-471|47|853|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-472|47|858|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-473|47|861|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-474|47|866|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-475|47|865|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-476|47|866|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-477|47|867|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-478|47|868|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-479|47|869|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-480|47|874|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-481|47|881|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-482|47|886|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-483|47|889|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-484|47|889|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-485|47|890|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-486|47|902|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-487|47|907|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-488|47|909|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-489|47|909|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-490|47|915|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-491|47|912|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-492|47|918|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-493|47|930|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-494|47|942|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-495|47|946|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-496|47|951|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-497|47|952|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-498|47|956|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-499|47|954|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-500|47|954|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-501|47|957|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-502|47|957|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-503|47|959|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-504|47|960|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-505|47|966|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-506|47|971|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-507|47|988|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-508|47|1014|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-509|47|1033|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-510|47|1033|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-511|47|1033|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-512|47|1033|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-513|47|1033|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-514|47|1|Other deterministic changes|Whole body|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-515|47|1|Other deterministic changes|Whole body|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-516|47|557|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-517|47|653|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-518|47|656|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-519|47|703|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-520|47|703|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-521|47|741|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-522|47|777|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-523|47|779|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-524|47|787|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-525|47|837|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-526|47|844|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-527|47|873|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-528|47|887|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-529|47|893|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-530|47|919|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-531|47|985|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-532|47|1006|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-533|47|1006|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-534|47|1012|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-535|47|1041|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-536|47|1098|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-537|47|1119|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-538|47|1123|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-539|47|1123|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-540|47|1123|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-541|47|1123|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-542|47|15|Other deterministic changes|Whole body|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-543|47|15|Other deterministic changes|Whole body|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-544|47|604|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-545|47|709|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-546|47|732|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-547|47|739|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-548|47|744|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-549|47|744|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-550|47|767|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-551|47|801|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-552|47|801|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-553|47|809|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-554|47|820|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-555|47|830|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-556|47|830|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-557|47|844|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-558|47|851|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-559|47|851|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-560|47|852|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-561|47|858|Other deterministic changes|Lower respiratory system|n/a|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-562|47|873|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-563|47|894|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-564|47|912|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-565|47|939|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-12-47|Contr 0,8/89 2/90|1|92|none (controls)|0|grays|External exposure|controls|566 (566 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-12-47-566|47|939|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-1|48|166|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-2|48|325|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-3|48|355|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 551 - sarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-4|48|401|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-5|48|422|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-6|48|448|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-7|48|451|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-8|48|495|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-9|48|501|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-10|48|510|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-11|48|515|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-12|48|529|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-13|48|536|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-14|48|537|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-15|48|555|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-16|48|556|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-17|48|565|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-18|48|566|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-19|48|571|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-20|48|573|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-21|48|577|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-22|48|591|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-23|48|592|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-24|48|597|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-25|48|604|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-26|48|607|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-27|48|613|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-28|48|613|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-29|48|613|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-30|48|618|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-31|48|619|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-32|48|621|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-33|48|624|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-34|48|624|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-35|48|633|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-36|48|634|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-37|48|635|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-38|48|638|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-39|48|642|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-40|48|642|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-41|48|645|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-42|48|646|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-43|48|646|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-44|48|653|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-45|48|653|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-46|48|662|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-47|48|664|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-48|48|666|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-49|48|670|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-50|48|670|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-51|48|674|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|benign,MPATH: 354 - cholangiocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-52|48|675|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-53|48|682|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-54|48|684|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-55|48|687|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-56|48|687|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-57|48|689|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 551 - sarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-58|48|689|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-59|48|691|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-60|48|697|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-61|48|701|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-62|48|705|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-63|48|708|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|benign,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-64|48|714|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-65|48|718|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-66|48|718|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-67|48|726|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-68|48|736|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-69|48|736|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-70|48|736|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-71|48|738|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-72|48|738|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-73|48|741|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-74|48|746|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-75|48|747|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-76|48|747|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-77|48|750|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-78|48|750|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-79|48|751|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-80|48|754|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-81|48|758|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-82|48|762|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-83|48|764|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-84|48|764|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-85|48|765|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-86|48|765|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-87|48|765|Neoplasia malignant|Liver among hepato-pancreatic system diseases|metastatic|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-88|48|765|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-89|48|766|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-90|48|767|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-91|48|768|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-92|48|770|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-93|48|773|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-94|48|778|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-95|48|778|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-96|48|781|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-97|48|784|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-98|48|785|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-99|48|786|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-100|48|791|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-101|48|791|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-102|48|792|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-103|48|795|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-104|48|799|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-105|48|800|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-106|48|800|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-107|48|804|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-108|48|808|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-109|48|809|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-110|48|809|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-111|48|811|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-112|48|814|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-113|48|823|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-114|48|826|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-115|48|830|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-116|48|830|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-117|48|834|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-118|48|837|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-119|48|837|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-120|48|840|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-121|48|840|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-122|48|841|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-123|48|841|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-124|48|841|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-125|48|842|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-126|48|844|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-127|48|851|Other deterministic changes|Lower respiratory system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-128|48|854|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-129|48|855|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-130|48|861|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-131|48|861|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-132|48|863|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-133|48|864|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-134|48|870|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-135|48|870|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-136|48|875|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-137|48|876|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-138|48|876|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-139|48|878|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-140|48|879|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-141|48|885|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-142|48|889|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-143|48|896|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-144|48|897|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-145|48|910|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-146|48|911|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-147|48|921|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-148|48|987|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-149|48|987|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-150|48|989|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-151|48|994|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-48|NE-uGy/h950-mGy 25,3/91|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 950 uGy/h|152 (152 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 3 m Cf 252 20.6.91 Mles 3 mois 2.5cGy 0.95mGy/h 1-152 ns 10.3.91 vie relle 53 101-152|2-12-48-152|48|1009|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-1|49|177|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-2|49|196|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-3|49|249|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-4|49|322|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-5|49|339|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-6|49|340|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-7|49|345|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-8|49|372|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-9|49|397|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-10|49|423|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-11|49|437|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-12|49|456|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-13|49|459|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-14|49|466|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-15|49|481|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-16|49|486|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-17|49|494|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-18|49|498|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-19|49|502|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-20|49|508|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-21|49|509|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-22|49|514|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-23|49|521|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-24|49|522|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-25|49|527|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-26|49|524|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-27|49|533|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|benign,MPATH: 219 - adnexal and skin appendage tumor|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-28|49|540|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-29|49|540|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-30|49|540|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-31|49|540|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-32|49|542|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-33|49|547|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-34|49|554|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-35|49|555|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-36|49|555|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-37|49|558|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-38|49|563|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-39|49|565|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-40|49|566|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-41|49|569|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-42|49|570|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|benign,MPATH: 446 - squamous cell carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-43|49|583|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-44|49|585|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-45|49|593|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-46|49|594|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-47|49|598|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-48|49|600|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-49|49|601|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-50|49|604|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-51|49|606|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-52|49|614|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-53|49|620|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-54|49|622|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-55|49|625|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-56|49|625|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-57|49|626|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-58|49|627|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-59|49|628|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-60|49|629|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-61|49|629|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-62|49|636|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-63|49|636|Neoplasia malignant|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-64|49|639|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-65|49|646|Neoplasia benign|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-66|49|646|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-67|49|647|Neoplasia malignant|Heart among cardiovascular system,MA: 0000072 - heart|,MPATH: 511 - Myeloproliferation (genetic)|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-68|49|647|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-69|49|644|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-70|49|642|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-71|49|648|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-72|49|649|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-73|49|653|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-74|49|651|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-75|49|651|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-76|49|661|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-77|49|664|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-78|49|667|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-79|49|667|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-80|49|669|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-81|49|670|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-82|49|670|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-83|49|670|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-84|49|671|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-85|49|671|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-86|49|675|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-87|49|682|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-88|49|682|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-89|49|684|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-90|49|685|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-91|49|688|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-92|49|686|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-93|49|692|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-94|49|692|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-95|49|695|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-96|49|693|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-97|49|697|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-98|49|697|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-99|49|699|Neoplasia malignant|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-100|49|701|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-101|49|702|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-102|49|703|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-103|49|702|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-104|49|707|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-105|49|707|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-106|49|705|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-107|49|708|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-108|49|708|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-109|49|710|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-110|49|713|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-111|49|713|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-112|49|713|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-113|49|715|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-114|49|716|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-115|49|716|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-116|49|717|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-117|49|717|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-118|49|717|Neoplasia malignant|Adrenal gland  among endocrine systems|metastatic|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-119|49|721|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-120|49|722|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-121|49|724|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-122|49|727|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-123|49|728|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-124|49|729|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-125|49|730|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-126|49|732|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-127|49|735|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-128|49|737|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-129|49|738|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-130|49|739|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-131|49|743|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-132|49|749|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-133|49|749|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-134|49|749|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-135|49|752|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-136|49|755|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-137|49|755|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-138|49|755|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-139|49|753|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-140|49|756|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-141|49|758|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-142|49|762|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-143|49|763|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-144|49|764|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-145|49|764|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-146|49|765|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-147|49|766|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-148|49|769|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-149|49|769|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-150|49|769|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-151|49|769|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-152|49|771|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-153|49|772|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-154|49|772|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-155|49|773|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-156|49|773|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-157|49|776|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-158|49|776|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-159|49|776|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-160|49|777|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-161|49|777|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-162|49|780|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-163|49|780|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-164|49|780|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-165|49|781|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-166|49|785|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-167|49|785|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-168|49|790|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-169|49|790|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-170|49|790|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-171|49|792|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-172|49|792|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-173|49|793|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-174|49|794|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-175|49|794|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-176|49|801|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-177|49|801|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-178|49|804|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-179|49|804|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-180|49|805|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-181|49|805|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-182|49|807|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-183|49|808|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-184|49|813|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-185|49|815|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|,MPATH: 331 - sertoli cell tumor|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-186|49|818|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-187|49|818|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-188|49|818|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-189|49|816|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-190|49|819|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|benign,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-191|49|825|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-192|49|827|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-193|49|827|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-194|49|827|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-195|49|828|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-196|49|829|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-197|49|833|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-198|49|833|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-199|49|834|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-200|49|834|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-201|49|836|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-202|49|839|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-203|49|840|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-204|49|840|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-205|49|846|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-206|49|846|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-207|49|848|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-208|49|849|Hyperplastic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-209|49|850|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-210|49|851|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-211|49|857|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-212|49|857|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-213|49|860|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-214|49|860|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-215|49|860|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-216|49|863|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-217|49|867|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-218|49|867|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-219|49|870|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-220|49|874|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-221|49|875|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-222|49|876|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-223|49|878|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-224|49|881|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-225|49|890|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-226|49|895|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-227|49|898|Neoplasia malignant|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-228|49|899|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-229|49|899|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-230|49|902|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-231|49|905|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-232|49|905|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-233|49|906|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-234|49|910|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-235|49|916|Other deterministic changes|Lower respiratory system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-236|49|919|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-237|49|923|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-238|49|923|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-239|49|923|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-240|49|923|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-241|49|926|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-242|49|926|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-243|49|931|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-244|49|938|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-245|49|939|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-246|49|940|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-247|49|946|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-248|49|948|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-249|49|959|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-250|49|966|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-251|49|980|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-252|49|980|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|metastatic,MPATH: 242 - hemangiosarcoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-253|49|980|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-254|49|983|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-49|NE-uGy/h760-mGy 25,3/91|1|427|neutrons C-252|25|grays|External exposure|initial dose rate 760 uGy/h|255 (255 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Old Adult|from age 14 to 14 m  Cf252 Mles 2.5cGy 0.758mGy/h 418J vie relle 153-161 non irr 164-211 58 350-407|2-12-49-255|49|1047|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-1|50|202|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-2|50|319|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-3|50|343|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-4|50|400|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-5|50|455|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-6|50|497|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-7|50|501|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-8|50|507|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-9|50|514|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-10|50|514|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-11|50|514|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-12|50|525|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-13|50|528|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-14|50|528|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-15|50|539|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-16|50|540|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-17|50|555|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-18|50|560|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-19|50|561|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-20|50|561|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-21|50|563|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-22|50|567|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-23|50|567|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-24|50|572|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-25|50|576|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-26|50|576|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-27|50|580|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-28|50|588|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-29|50|588|Neoplasia systemic|Haematolymphatic system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-30|50|597|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-31|50|597|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-32|50|599|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 426 - leiomyosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-33|50|602|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-34|50|608|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-35|50|610|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-36|50|606|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-37|50|611|Neoplasia malignant|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-38|50|614|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-39|50|620|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-40|50|624|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-41|50|626|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-42|50|627|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-43|50|637|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-44|50|644|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-45|50|644|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-46|50|644|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-47|50|648|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-48|50|653|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-49|50|658|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-50|50|658|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-51|50|659|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-52|50|665|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-53|50|665|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-54|50|667|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-55|50|667|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-56|50|668|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-57|50|669|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-58|50|673|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-59|50|670|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-60|50|674|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-61|50|674|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-62|50|674|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-63|50|674|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-64|50|675|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-65|50|676|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-66|50|676|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-67|50|679|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-68|50|682|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-69|50|689|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-70|50|695|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-71|50|696|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-72|50|696|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-73|50|700|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 214 - chronic inflammation|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-74|50|701|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-75|50|703|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-76|50|703|Neoplasia unclassified|Nervous system and special sense organs,MA: 0000261 - eye|,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-77|50|703|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-78|50|707|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-79|50|711|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-80|50|714|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-81|50|714|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-82|50|716|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-83|50|717|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-84|50|717|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-85|50|717|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-86|50|717|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-87|50|718|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-88|50|718|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-89|50|718|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-90|50|718|Neoplasia malignant|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-91|50|721|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-92|50|721|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-93|50|721|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-94|50|724|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-95|50|725|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-96|50|725|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-97|50|728|Neoplasia malignant|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-98|50|728|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-99|50|728|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-100|50|735|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-101|50|735|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-102|50|736|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-103|50|737|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|metastatic lung tumour,MPATH: 446 - squamous cell carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-104|50|738|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-105|50|742|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-106|50|744|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-107|50|749|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-108|50|749|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-109|50|749|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-110|50|749|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-111|50|747|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-112|50|750|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-113|50|752|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-114|50|753|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-115|50|757|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 551 - sarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-116|50|757|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-117|50|757|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-118|50|758|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-119|50|759|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-120|50|759|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-121|50|760|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-122|50|763|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-123|50|763|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-124|50|763|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-125|50|764|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-126|50|770|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-127|50|770|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-128|50|771|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-129|50|773|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-130|50|774|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-131|50|777|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-132|50|775|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-133|50|778|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-134|50|780|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-135|50|781|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-136|50|784|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 551 - sarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-137|50|784|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-138|50|784|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-139|50|785|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-140|50|786|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-141|50|788|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-142|50|788|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-143|50|792|Hyperplastic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-144|50|792|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-145|50|793|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-146|50|795|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-147|50|798|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-148|50|798|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-149|50|798|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-150|50|800|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-151|50|800|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-152|50|800|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-153|50|802|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-154|50|803|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-155|50|806|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-156|50|808|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-157|50|812|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-158|50|812|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-159|50|812|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-160|50|813|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|metastatic,MPATH: 365 - mesothelioma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-161|50|813|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-162|50|819|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-163|50|815|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-164|50|826|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-165|50|827|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-166|50|827|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-167|50|828|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-168|50|829|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-169|50|830|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-170|50|830|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-171|50|833|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-172|50|833|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-173|50|833|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-174|50|833|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-175|50|834|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-176|50|834|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-177|50|834|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-178|50|837|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-179|50|840|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-180|50|840|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-181|50|840|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-182|50|844|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-183|50|847|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-184|50|848|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-185|50|848|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-186|50|848|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-187|50|851|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-188|50|851|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-189|50|851|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-190|50|854|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-191|50|863|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-192|50|863|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-193|50|865|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-194|50|868|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-195|50|869|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-196|50|869|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-197|50|870|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-198|50|871|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-199|50|871|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-200|50|875|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-201|50|875|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-202|50|875|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-203|50|876|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-204|50|876|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-205|50|877|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-206|50|877|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-207|50|877|Neoplasia unclassified|Nervous system and special sense organs,MA: 0000261 - eye|,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-208|50|879|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-209|50|882|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-210|50|882|Neoplasia malignant|Reproductive system,MA: 0000404 - prostate gland|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-211|50|880|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-212|50|886|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-213|50|889|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-214|50|891|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-215|50|892|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-216|50|896|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-217|50|894|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-218|50|898|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-219|50|899|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-220|50|904|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-221|50|907|Other deterministic changes|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-222|50|910|Neoplasia malignant|Lower respiratory system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-223|50|910|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-224|50|914|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-225|50|914|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-226|50|925|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-227|50|928|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-228|50|928|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-229|50|929|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-230|50|938|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-231|50|938|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-232|50|948|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-233|50|949|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-234|50|956|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-235|50|956|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-236|50|965|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-237|50|966|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-238|50|966|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-239|50|967|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-240|50|970|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-241|50|975|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-242|50|975|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-243|50|977|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-244|50|977|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-245|50|977|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|benign,MPATH: 354 - cholangiocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-246|50|1005|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-247|50|1022|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-248|50|1064|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-12-50|NE-uGy/h3.58mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 3.58 uGy/h|249 (249 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252 (B3)ns 1.10.91 2.4cGy/1an 3.58Gy/h irr 15.2.91 vie rel 49 67201-67249|2-12-50-249|50|1158|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-1|51|287|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-2|51|307|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-3|51|312|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-4|51|514|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-5|51|595|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-6|51|613|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-7|51|619|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-8|51|620|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-9|51|625|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-10|51|658|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-11|51|665|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-12|51|666|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-13|51|668|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-14|51|672|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-15|51|672|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-16|51|697|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-17|51|697|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-18|51|702|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-19|51|708|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-20|51|716|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-21|51|717|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-22|51|725|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-23|51|729|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-24|51|730|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-25|51|739|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-26|51|746|Neoplasia malignant|Adrenal gland  among endocrine systems|metastatic|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-27|51|746|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-28|51|778|Hyperplastic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-29|51|779|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-30|51|781|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-31|51|788|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-32|51|794|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 409 - fibrous histiocytoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-33|51|795|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-34|51|800|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-35|51|801|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-36|51|802|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-37|51|805|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|metastatic,MPATH: 365 - mesothelioma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-38|51|812|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-39|51|819|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-40|51|824|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-41|51|824|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-42|51|862|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-43|51|868|Neoplasia unclassified|Thyroid and parathyroid glands among endocrine systems,MA: 0002676 - parathyroid gland capsule|benign,MPATH: 218 - neoplasm|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-44|51|882|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-45|51|891|Other deterministic changes|Lower respiratory system|n/a|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-46|51|917|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-47|51|926|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-48|51|932|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-49|51|941|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-50|51|941|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-12-51|NE-uGy/h7.72-mGy 25,10/90|1|92|neutrons C-252|25|grays|External exposure|initial dose rate 7.72 uGy/h|51 (51 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|from age 3 to 15 m  Cf252(B3)ns1.10.90 5.3cGy/1an 7.72Gy/h irra.15.2.91 vie rel 51 67301-67351|2-12-51-51|51|941|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
